TransMedics Forecasts Q4 EPS $0.41 (+115.8%), Reveals Two March Investor Presentations
TransMedics is expected to report Q4 results on Feb 24 with an EPS forecast of $0.41, a 115.8% year-over-year increase, and revenues projected at $155.91 million, up 28.2%. Management will present at the TD Cowen Health Care Conference March 2 and the Oppenheimer Healthcare MedTech & Services Conference March 16.
1. Q4 Earnings Forecast
TransMedics is scheduled to report its quarter ended December 2025 results on February 24, with analysts projecting EPS of $0.41, representing a 115.8% increase compared to the prior-year period’s $0.19. This jump reflects strong anticipated demand for the company’s organ perfusion platforms.
2. Revenue Projections and Growth
Consensus estimates forecast revenue of $155.91 million for Q4, up 28.2% year-over-year from $121.6 million, driven by increased adoption of TransMedics’ lung, heart, and liver perfusion systems. Stability in these projections over the past month indicates sustained analyst confidence.
3. Upcoming Investor Conferences
Management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston on March 2 at 1:50 p.m. EST and present virtually at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16 at 10:00 a.m. EST. Webcasts will be available on the company’s Investor Relations website.
4. Potential Market Impact
The combination of robust earnings expectations and scheduled investor presentations provides catalysts for share volatility. Positive Q4 results or insightful commentary during these events could spur upward revisions in analyst estimates and influence near-term stock performance.